Embla provides sleep diagnostics including polysomnography (PSG), home sleep testing and sleep diagnostic solutions including Embletta home sleep testing devices and three PSG platforms including Enterprise Sleep Business Management Systems, RemLogic, Sandman and Rembrandt.
Natus CEO Jim Hawkins said additionally, with approximately 40% of Embla’s revenue coming from international markets, this acquisition positions Natus as the leader in sleep diagnostics outside the US.
Natus products include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices.
